The US Department of Health and Human Services has declared the conclusion of the monitoring period for the hantavirus, indicating that the outbreak has eased. This decision reflects a significant reduction in cases and a return to normal public health operations, according to Al Jazeera.

The World Health Organisation (WHO) has expressed concern over a significant outbreak of Bundibugyo virus disease (BVD), a strain of Ebola, which has resulted in 454 fatalities. The situation is worsening, particularly in the Democratic Republic of Congo, prompting urgent attention from health authorities.

A trial for potential treatments targeting the Ebola virus responsible for the current outbreak in the Democratic Republic of Congo has commenced, as announced by the World Health Organization (WHO). The first patient has been enrolled in the trial, which follows reports of over 1,400 cases and 438 deaths related to the outbreak, according to WHO chief Tedros Adhanom Ghebreyesus.

Uganda recently closed its border with the Democratic Republic of Congo to prevent the spread of Ebola, as the Congo faces a significant outbreak with over 1,000 suspected and confirmed cases and more than 250 deaths reported as of May 27, 2026, according to the U.S. Centers for Disease Control. Public health experts suggest that such border closures may not be the most effective strategy in managing the outbreak.

According to the World Health Organization, the Democratic Republic of the Congo (DRC) has reported 1,460 confirmed Ebola cases and 432 deaths as of Wednesday, marking the highest level of new cases since the outbreak began. The case fatality rate stands at approximately 31 percent, with cases recorded across 36 health zones in three provinces.

The World Health Organization (WHO) is set to launch a clinical trial in the Democratic Republic of the Congo (DRC) next week to assess the effectiveness of two antiviral treatments, MBP134 and remdesivir, in reducing mortality among patients infected with Bundibugyo virus disease. This initiative comes as reported cases of the disease exceed 1,000. The trial will evaluate the treatments both individually and in combination, with preparations now complete.